ombrabulin experimental drug candidate discovered ajinomoto developed ombrabulin combretastatin derivative exerts antitumor effect disrupting formation blood vessels needed tumor granted orphan drug status european medicines agency april january sanofi said discontinued development ombrabulin disappointing results phase iii clinical httpsenwikipediaorgwikiombrabulin